<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>SBIR Phase I:  A high throughput microfluidic platform to accelerate biomanufacturing transitions in the COVID-19 response</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>09/01/2020</AwardEffectiveDate>
<AwardExpirationDate>08/31/2021</AwardExpirationDate>
<AwardTotalIntnAmount>256000.00</AwardTotalIntnAmount>
<AwardAmount>256000</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>07070000</Code>
<Directorate>
<Abbreviation>ENG</Abbreviation>
<LongName>Directorate For Engineering</LongName>
</Directorate>
<Division>
<Abbreviation>IIP</Abbreviation>
<LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Erik Pierstorff</SignBlockName>
<PO_EMAI>epiersto@nsf.gov</PO_EMAI>
<PO_PHON>7032922165</PO_PHON>
</ProgramOfficer>
<AbstractNarration>The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project aims to address a key challenge in the response to COVID-19, namely manufacturing sufficient quantities of novel therapeutics and vaccines. This project can shorten the development times of drugs by as much as 6 months, accelerating translation of new therapeutics. This technology will also enable more testing, thereby increasing the performance and potentially reducing the side effects of these drugs.&lt;br/&gt;&lt;br/&gt;This SBIR Phase I project advances the manufacturing of biologics, which starts with a high performing clonal cell line derived (by definition) from a single cell. Developing such a cell line today takes up to 6 months due to iterative screening and testing to assure quality and performance. The proposed project aims to enable selection of a high performing cell clone in one day compared to many months by using a proprietary single cell proteomics platform, at an unprecedented throughput rather than lengthy, iterative selection, clonal expansion and analytics.&lt;br/&gt;&lt;br/&gt;This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.</AbstractNarration>
<MinAmdLetterDate>09/02/2020</MinAmdLetterDate>
<MaxAmdLetterDate>10/14/2020</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.041</CFDA_NUM>
<NSF_PAR_USE_FLAG>1</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>2032448</AwardID>
<Investigator>
<FirstName>Konstantinos</FirstName>
<LastName>Tsioris</LastName>
<PI_MID_INIT/>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Konstantinos Tsioris</PI_FULL_NAME>
<EmailAddress>kosta.tsioris@gmail.com</EmailAddress>
<PI_PHON>6179107825</PI_PHON>
<NSF_ID>000765558</NSF_ID>
<StartDate>09/02/2020</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>ONECYTE BIOTECHNOLOGIES, INC.</Name>
<CityName>Somerville</CityName>
<CountyName>MIDDLESEX</CountyName>
<ZipCode>021441129</ZipCode>
<PhoneNumber>6179107825</PhoneNumber>
<StreetAddress>99 North St</StreetAddress>
<StreetAddress2/>
<CountryName>United States</CountryName>
<StateName>Massachusetts</StateName>
<StateCode>MA</StateCode>
<CONGRESSDISTRICT>07</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>MA07</CONGRESS_DISTRICT_ORG>
<ORG_DUNS_NUM>080978326</ORG_DUNS_NUM>
<ORG_LGL_BUS_NAME>ONECYTE BIOTECHNOLOGIES, INC.</ORG_LGL_BUS_NAME>
<ORG_PRNT_DUNS_NUM/>
</Institution>
<Performance_Institution>
<Name><![CDATA[Onecyte Biotechnologies, Inc.]]></Name>
<CityName>Somerville</CityName>
<CountyName>MIDDLESEX</CountyName>
<StateCode>MA</StateCode>
<ZipCode>021394307</ZipCode>
<StreetAddress><![CDATA[500 Main St, Room 76-041C]]></StreetAddress>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>Massachusetts</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>07</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>MA07</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<ProgramElement>
<Code>5371</Code>
<Text>SBIR Phase I</Text>
</ProgramElement>
<ProgramReference>
<Code>008E</Code>
<Text>Gene and Drug Delivery</Text>
</ProgramReference>
<ProgramReference>
<Code>096Z</Code>
<Text>COVID-19 Research</Text>
</ProgramReference>
<ProgramReference>
<Code>8038</Code>
<Text>Biotechnology</Text>
</ProgramReference>
<Appropriation>
<Code>0120</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<FUND_OBLG>2020~256000</FUND_OBLG>
</Award>
</rootTag>
